{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:16Z","timestamp":1794932416262,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.128969","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:10:35Z","timestamp":1787926235000},"page":"128969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study"],"prefix":"10.1016","volume":"91","author":[{"given":"Abhijeet","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damaris","family":"Jepkosgei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mwachari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Jalang'o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kitwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Kagecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Leboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boniface","family":"Kitungulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hudson","family":"Kigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pius","family":"Mutuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrell A.","family":"Tobolowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lang'at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A.","family":"Mainou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Wafula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Herman-Roloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Koech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6261","key":"10.1016\/j.vaccine.2026.128969_bb0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1126\/science.aad7294","article-title":"Eradicating polio","volume":"350","author":"Adams","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.vaccine.2026.128969_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128969_bb0015","unstructured":"Global Polio Eradication Initiative. 2025. https:\/\/polioeradication.org\/ (accessed 11 September 2025)."},{"key":"10.1016\/j.vaccine.2026.128969_bb0020","series-title":"Vaccines","first-page":"598","article-title":"Poliovirus vaccine-live","author":"Sutter","year":"2012"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128969_bb0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6738","key":"10.1016\/j.vaccine.2026.128969_bb0030","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.adu6580","article-title":"Global withdrawal of Sabin oral poliovirus type 2 vaccine in 2016","volume":"387","author":"Molodecky","year":"2025","journal-title":"Science (New York, NY)"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128969_bb0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"10193","key":"10.1016\/j.vaccine.2026.128969_bb0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2026.128969_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"Saez-Llorens","year":"2021","journal-title":"Lancet"},{"issue":"10371","key":"10.1016\/j.vaccine.2026.128969_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(22)02397-2","article-title":"Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial","volume":"401","author":"Zaman","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128969_bb0055","article-title":"Monitoring the risk of type-2 circulating vaccine-derived poliovirus emergence during roll-out of type-2 novel oral polio vaccine","volume":"12","author":"Peak","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128969_bb0060","series-title":"Best practice for monitoring the quality of polio eradication campaign performance","author":"The Global Polio Eradication Initiative","year":"2025"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128969_bb0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(23)00139-1","article-title":"Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial","volume":"23","author":"Wilkinson","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128969_bb0070","series-title":"Meeting of the strategic advisory group of experts on immunization, September 2024: conclusions and recommendations","volume":"49","author":"World Health Organization","year":"2024"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128969_bb0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1473-3099(23)00631-X","article-title":"Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in the Gambia: an observational cohort study","volume":"24","author":"Bashorun","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128969_bb0080","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1016\/S2214-109X(22)00412-0","article-title":"Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021","volume":"10","author":"Mirzoev","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128969_bb0085","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1016\/S2214-109X(23)00116-X","article-title":"Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey","volume":"11","author":"Kennedy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128969_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126978","article-title":"Impact of novel oral poliovirus type 2 vaccination campaigns: a seroprevalence survey in Nigeria, 2022","volume":"54","author":"Iliyasu","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128969_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128969_bb0100","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128969_bb0105","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2214-109X(24)00552-7","article-title":"Three-dose immunogenicity of the type 2 novel oral poliovirus vaccine in a campaign setting in Tajikistan: a follow-up study","volume":"13","author":"Mirzoev","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128969_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128969_bb0115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review","volume":"13","author":"Patriarca","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128969_bb0120","first-page":"529","article-title":"The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomized controlled trial","volume":"215","author":"John","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128969_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1749-6632.1995.tb44462.x","article-title":"Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination","volume":"754","author":"Sutter","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128969_bb0130","series-title":"Vaccines","first-page":"1576","article-title":"Poliovirus vaccine-inactivated","author":"Vidor","year":"2012"},{"issue":"10191","key":"10.1016\/j.vaccine.2026.128969_bb0135","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/S0140-6736(19)30503-3","article-title":"Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial","volume":"393","author":"Snider","year":"2019","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128969_bb0140","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128969_bb0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(23)00519-4","article-title":"Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic","volume":"24","author":"Rivera Mejia","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128969_bb0150","first-page":"115","article-title":"Immunization in India with trivalent and monovalent oral poliovirus vaccines of enhanced potency","volume":"54","author":"John","year":"1976","journal-title":"Bull World Health Organ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:50:11Z","timestamp":1794930611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0264410X26007784"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128969","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128969"}}